Natalie Valle Guzman University positionResearcher DepartmentsInstitutesBehavioural and Clinical Neuroscience Institute and MRC Cambridge Stem Cell Institute Research ThemeInterestsI work on different studies investigating disorders of motivation and impulsivity, both with healthy volunteers as with patients with various disorders. I am responsible for participant recruitment and management of the research, and I help run several studies with TMS and cognitive testing. Research Focus
EquipmentNeuropsychological testing Randomised control trials TMS CollaboratorsNo collaborators listed Associated News ItemsPublications2021Weidacker K, Kvamme T, Whiteford S, Valle Guzman N, Voon V. (2021), “Incentives and voluntary stopping: the intentional hand task.” Cognition 206, 104504 2020Li, W., Lao-Kaim, N. P., Roussakis, A.-A., Martín-Bastida, A., Valle-Guzman, N., Paul, G., . . . Piccini, P. (2020), “Longitudinal functional connectivity changes related to dopaminergic decline in Parkinson’s disease.” NeuroImage 28, 102409 2018Li W, Lao-Kaim NP, Roussakis AA, Martín-Bastida A, Valle-Guzman N, Paul G, Loane C, Widner H, Politis M, Foltynie T, Barker RA, Piccini P (2018), “11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study” Mov Disord Jan;33(1):117-127 2017Lakshminarayana R, Wang D, Burn D, Chaudhuri KR, Galtrey C, Guzman NV, Hellman B, Ben James, Pal S, Stamford J, Steiger M, Stott RW, Teo J, Barker RA, Wang E, Bloem BR, van der Eijk M, Rochester L, Williams A (2017), “Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson's disease” NPJ Parkinsons Dis. Jan 9;3:2 Martin-Bastida A, Lao-Kaim NP, Loane C, Politis M, Roussakis AA, Valle-Guzman N, Kefalopoulou Z, Paul-Visse G, Widner H, Xing Y, Schwarz ST, Auer DP, Foltynie T, Barker RA, Piccini (2017), “Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility” Eur J Neurol Feb;24(2):357-365 2016Loane C, Politis M, Kefalopoulou Z, Valle-Guzman N, Paul G, Widner H, Foltynie T, Barker RA, Piccini P. (2016), “Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study” Mov Disord Jul;31(7):1020-6 2014Downing NR, Kim JI, Williams JK, Long JD, Mills JA, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2014), “WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease.” Eur J Hum Genet 22(8):958-63 Details Long JD, Paulsen JS, Marder K, Zhang Y, Kim JI, Mills JA, Researchers of the PREDICT-HD Huntington's Study Group (2014), “Tracking motor impairments in the progression of Huntington's disease.” Mov Disord 29(3):311-9 Details Moore SF, Guzman NV, Mason SL, Williams-Gray CH, Barker RA (2014), “Which Patients with Parkinson's Disease Participate in Clinical Trials? One Centre's Experiences with a New Cell Based Therapy Trial (TRANSEURO).” J Parkinsons Dis Details Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA (2014), “Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.” Lancet 383(9923):1138-46 Details 2013Aylward EH, Harrington DL, Mills JA, Nopoulos PC, Ross CA, Long JD, Liu D, Westervelt HK, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2013), “Regional atrophy associated with cognitive and motor function in prodromal Huntington disease.” J Huntingtons Dis 2(4):477-89 Details Begeti F, Tan AY, Cummins GA, Collins LM, Guzman NV, Mason SL, Barker RA (2013), “The Addenbrooke's Cognitive Examination-Revised accurately detects cognitive decline in Huntington's disease.” J Neurol 260(11):2777-85 Details Epping EA, Mills JA, Beglinger LJ, Fiedorowicz JG, Craufurd D, Smith MM, Groves M, Bijanki KR, Downing N, Williams JK, Long JD, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2013), “Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study.” J Psychiatr Res 47(10):1423-31 Details Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ, REGISTRY investigators of the European Huntington's Disease Network (2013), “Suicidal ideation in a European Huntington's disease population.” J Affect Disord 151(1):248-58 Details Metzger S, Walter C, Riess O, Roos RA, Nielsen JE, Craufurd D, REGISTRY Investigators of the European Huntington’s Disease Network, Nguyen HP (2013), “The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients.” PLoS One 8(7):e68951 Details Vittori A, Orth M, Roos RA, Outeiro TF, Giorgini F, Hollox EJ, Registry investigators of the European Huntington's Disease Network (2013), “?-Defensin genomic copy number does not influence the age of onset in Huntington's Disease.” J Huntingtons Dis 2(1):107-24 Details 2009Restifo K, Akse J, Guzman NV, Benjamins C, Dick K (2009), “A pilot study of self-esteem as a mediator between family factors and depressive symptoms in young adult university students.” J Nerv Ment Dis 197(3):166-71 Details |